Can I Take Calcium with Egrifta (Tesamorelin)?

Print or save as PDF

Key numbers

  • 2,500 mg a dayTolerable upper limit of calcium from food and supplements for adults 19 to 50Source: pmc.ncbi.nlm.nih.gov, as cited Nov 7, 2026
  • 1,000 mg a dayRecommended calcium intake for adults 19 to 50, food and supplements combinedSource: pmc.ncbi.nlm.nih.gov, as cited Nov 7, 2026
  • 2 hoursCipro timing gap from calcium-containing products, 2 hours before or 6 hours afterSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
  • 20% to 25%Drop in levothyroxine absorption from calcium, any salt form, in healthy adultsSource: pubmed.ncbi.nlm.nih.gov, as cited Nov 7, 2026

From the public record

FDA adverse event reports listing both calcium and tesamorelin

Through 2026-10-28, FDA had received 21 adverse event reports that list both calcium and tesamorelin, out of 121,344 reports for calcium and 2,771 for tesamorelin. A joint report shows both were recorded for the same person, not that they interacted.

FDA adverse event reports listing both calcium and tesamorelin: the figures
MeasureValue
Reports listing both drugs21
All reports for calcium121,344
All reports for tesamorelin2,771
Joint reports naming peripheral swelling4
Joint reports naming arthralgia3
Joint reports naming back pain2
Joint reports naming hypoaesthesia2

Source: FDA Adverse Event Reporting System (FAERS) via openFDA, data as of Oct 28, 2026

How this was calculated

Counted FAERS reports that list both active substances in any role, then the symptom terms named most often in those reports. Terms about product use rather than symptoms were left out. The events may relate to either drug, to another drug, or to the illness.

Scope: Reports listing both calcium and tesamorelin as single-ingredient active substances, any brand, suspect or concomitant

FAERS reports are unverified and do not prove the drug caused the event. Reporting rises with use, publicity and lawsuits, so these counts cannot give rates or risks and cannot be compared between drugs. Joint reports are not evidence of an interaction.

Download the data (CSV)

  • Drug / tesamorelin, a once-daily subcutaneous injection: 1.4 mg for Egrifta SV, 1.28 mg for Egrifta WR, which the labels call not substitutable [1][2]
  • Approved use / reduction of excess abdominal fat in HIV-infected adults with lipodystrophy; not indicated for weight loss [1]
  • Interactions the labels list / drugs metabolized by CYP450 enzymes, and glucocorticoid replacement [1][2]
  • Calcium form / carbonate taken with a meal; citrate without food and preferred with acid-suppressing drugs [3]
  • Calcium adult RDA / 1,000 mg a day at ages 19 to 50; 1,200 mg for women 51 to 70 and everyone 71 and older [4]
  • Calcium upper limit / 2,500 mg a day at ages 19 to 50; 2,000 mg a day at 51 and older [4]
  • Calcium timing that does matter / the Cipro label says to take Cipro at least 2 hours before or 6 hours after calcium-containing products [5]

The short answer

Calcium carbonate and calcium citrate are over-the-counter oral supplements; the FDA Daily Value printed on supplement labels is 1,300 mg [6]. Tesamorelin is a prescription peptide injected under the skin of the abdomen once a day, at 1.4 mg for Egrifta SV and 1.28 mg for Egrifta WR [1][2]. No formal metabolism studies have been performed in humans [1][2].

The drug interactions sections of the Egrifta SV and Egrifta WR labels cover two subjects: drugs known to be metabolized by CYP450 liver enzymes, and glucocorticoid replacement, where patients on cortisone acetate or prednisone for hypoadrenalism may need higher maintenance or stress doses after starting tesamorelin [1][2]. Calcium is not named in either section.

What the Egrifta labels ask prescribers to track

Tesamorelin binds and stimulates human GRF receptors on pituitary somatotroph cells, increasing the pituitary's own output of growth hormone, which in turn raises IGF-1 and IGFBP-3 [1].

The label asks prescribers to track IGF-1 and glucose. Among patients treated for 26 weeks, 47% had IGF-1 above 2 standard deviation scores and 36% above 3; among those treated for 52 weeks, 34% and 23% [1]. The label says to monitor IGF-1 and to consider stopping tesamorelin for persistent elevations, for example above 3 SDS, particularly when the fat-loss response is not robust [1]. On glucose, HbA1c of 6.5% or higher developed in 5% of tesamorelin patients versus 1% on placebo by week 26, a hazard ratio of about 3.3 (95% CI 1.4 to 9.6), and the label says to evaluate glucose before and during therapy [1].

The label's warnings center on neoplasms, IGF-1, glucose intolerance, fluid retention, hypersensitivity reactions and injection-site reactions [1][2].

What calcium does on its own

Calcium has its own dose ceiling and its own set of signals, independent of tesamorelin. The Institute of Medicine's 2011 recommended intake for adults is 1,000 mg a day at ages 19 to 50, 1,200 mg for women 51 to 70 and for everyone 71 and older, counting food and supplements together [4]. The tolerable upper intake level, the point above which adverse events become a concern, is 2,500 mg a day for adults 19 to 50 and 2,000 mg a day for adults 51 and older [4].

Absorption falls as the dose rises. In a study of healthy women taking calcium with meals, fractional absorption averaged 64.0% at a 15 mg load and 28.6% at a 500 mg load [7]. One review puts the maximum amount of elemental calcium to take at one time at 500 mg [3].

Two safety signals are worth knowing. In the Women's Health Initiative trial of 36,282 postmenopausal women given 1,000 mg calcium as carbonate plus 400 IU vitamin D3 daily for an average of 7 years, kidney stones increased (hazard ratio 1.17, 95% CI 1.02 to 1.34) [8]. A 2010 BMJ meta-analysis of calcium supplements at 500 mg a day or more found, in the five trials with patient-level data (8,151 participants, median 3.6 years), myocardial infarction in 143 people on calcium versus 111 on placebo (hazard ratio 1.31, 95% CI 1.02 to 1.67); stroke and death were not significantly increased, and these were secondary analyses of trials not designed for cardiovascular outcomes, so the question is unsettled [9][10].

On benefit, the US Preventive Services Task Force found adequate evidence that 1,000 mg or less of calcium with 400 IU or less of vitamin D daily gives no primary fracture-prevention benefit in community-dwelling postmenopausal women [11].

Calcium timing rules that come from other drugs

The Egrifta labels do not list calcium as an interaction. Calcium does have documented interactions with other medicines that people with HIV may also take.

Levothyroxine. In 20 hypothyroid patients taking 1,200 mg a day of elemental calcium as carbonate together with their levothyroxine for 3 months, mean free T4 fell from 17 to 15 pmol/L and returned to 18 pmol/L after calcium stopped [12]. In 8 healthy adults, 500 mg of elemental calcium as carbonate, citrate or acetate each reduced single-dose levothyroxine absorption by about 20% to 25%, so switching to citrate does not avoid the effect [13].

Ciprofloxacin. The Cipro label says to take it at least 2 hours before or 6 hours after products containing calcium, iron or zinc, because absorption drops. The label says dairy products or calcium-fortified juice alone should be avoided with Cipro, but that Cipro may be taken with a meal that contains them [5].

Thiazide diuretics. A systematic review reports that thiazides combined with calcium and vitamin D supplements may cause hypercalcemia in older people and in those with compromised kidney function or hyperparathyroidism [14].

Bottom line

Neither Egrifta label lists calcium as an interaction, and the monitoring the labels ask for is IGF-1 and glucose [1][2]. The useful detail on calcium is its own dose ceiling and its interactions with other medicines.

Check what you know

Think you have it? Try 5 quick questions and see what the article says.

1. According to the Egrifta labels, which two subjects do the drug interactions sections cover?

Question 1 of 5

Score: 0 right, 0 of 5 answered

Questions worth asking

Choose the questions you want to keep

What interactions do the Egrifta labels list?
The Egrifta SV and Egrifta WR drug interactions sections cover drugs metabolized by CYP450 liver enzymes and glucocorticoid replacement. Patients receiving glucocorticoids for previously diagnosed hypoadrenalism may need higher maintenance or stress doses after starting tesamorelin, and cortisone acetate and prednisone may be affected more than other steroids [1][2].
Which calcium form is easier to take?
Calcium carbonate should be taken with a meal for best absorption, while calcium citrate can be taken without food and is the preferred form for people with achlorhydria or who take H2 blockers or proton pump inhibitors [3].
How much calcium is too much?
The tolerable upper intake level is 2,500 mg a day for adults 19 to 50 and 2,000 mg a day for adults 51 and older, from food and supplements combined [4]. In the Women's Health Initiative, 1,000 mg of calcium as carbonate plus 400 IU of vitamin D3 daily raised kidney stones over 7 years (hazard ratio 1.17, 95% CI 1.02 to 1.34) [8].
Does calcium citrate avoid the levothyroxine interaction?
No. In a study of 8 healthy adults, 500 mg of elemental calcium as carbonate, citrate or acetate each reduced single-dose levothyroxine absorption by about 20% to 25% [13].
Show all 14 referencesHide references
  1. U.S. National Library of Medicine, DailyMed. Egrifta SV (tesamorelin) for injection, 2 mg vial prescribing information. Egrifta SV (tesamorelin) for injection, 2 mg vial label
  2. U.S. National Library of Medicine, DailyMed. Egrifta WR (tesamorelin) for injection, 11.6 mg vial prescribing information. Egrifta WR (tesamorelin) for injection, 11.6 mg vial label
  3. Straub DA. Calcium supplementation in clinical practice: a review of forms, doses, and indications. Nutr Clin Pract. 2007;22(3):286-96.
  4. The 2011 Report on Dietary Reference Intakes for Calcium and Vitamin D from the Institute of Medicine: What Clinicians Need to Know - PMC.
  5. U.S. National Library of Medicine, DailyMed. Cipro (ciprofloxacin) (ciprofloxacin hydrochloride) prescribing information. Cipro (ciprofloxacin) (ciprofloxacin hydrochloride) label
  6. Daily Value on the Nutrition and Supplement Facts Labels | FDA.
  7. Heaney RP, Weaver CM, Fitzsimmons ML. Influence of calcium load on absorption fraction. J Bone Miner Res. 1990;5(11):1135-8.
  8. Jackson RD, LaCroix AZ, Gass M, Wallace RB, Robbins J, Lewis CE, et al. Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med. 2006;354(7):669-83.
  9. Bolland MJ, Avenell A, Baron JA, Grey A, MacLennan GS, Gamble GD, et al. Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis. BMJ. 2010;341:c3691.
  10. Bolland MJ, Grey A, Avenell A, Gamble GD, Reid IR. Calcium supplements with or without vitamin D and risk of cardiovascular events: reanalysis of the Women's Health Initiative limited access dataset and meta-analysis. BMJ. 2011;342:d2040.
  11. US Preventive Services Task Force, Grossman DC, Curry SJ, Owens DK, Barry MJ, Caughey AB, et al. Vitamin D, Calcium, or Combined Supplementation for the Primary Prevention of Fractures in Community-Dwelling Adults: US Preventive Services Task Force Recommendation Statement. JAMA. 2018;319(15):1592-1599.
  12. Singh N, Singh PN, Hershman JM. Effect of calcium carbonate on the absorption of levothyroxine. JAMA. 2000;283(21):2822-5.
  13. Zamfirescu I, Carlson HE. Absorption of levothyroxine when coadministered with various calcium formulations. Thyroid. 2011;21(5):483-6.
  14. Robien K, Oppeneer SJ, Kelly JA, Hamilton-Reeves JM. Drug-vitamin D interactions: a systematic review of the literature. Nutr Clin Pract. 2013;28(2):194-208.
Evidence overview for Can I Take Calcium with Egrifta (Tesamorelin)?